Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light
Abstract
Monkeypox virus has recently emerged from endemic foci in Africa and, since October 20, 2022, more than 73,000 human infections have been reported by the CDC from over 100 countries that historically have not reported monkeypox cases. The detection of virus in skin lesions, blood, semen, and saliva of infected patients with monkeypox infections raises the potential for disease transmission via routes that have not been previously documented, including by blood and plasma transfusions. Methods for protecting the blood supply against the threats of newly emerging disease agents exist and include Pathogen Reduction Technologies (PRT) which utilize photochemical treatment processes to inactivate pathogens in blood while preserving the integrity of plasma and cellular components. Such methods have been employed broadly for over 15 years, but effectiveness of these methods under routine use conditions against monkeypox virus has not been reported.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 20, 2023
- Source ID
- 10.1371/journal.pone.0278862
Entities
People
- Elizabeth J. Sullivan
- Izabela K. Ragan
- Lindsay Hartson
- Raymond P Goodrich
- Richard A. Bowen
Organizations
- Colorado State University